NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date and time:** Thursday 11 November 2021

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Megan John [Chair] Present for all items
2. James Avery Present for all items
3. Martin Bradley Present for all items
4. Dr Matthew Bradley Present for all items
5. Professor Sofia Dias Present for all items
6. Professor Rachel Elliott Present for all items
7. Professor Paula Ghaneh Present for all items
8. Chris Herring Present for all items
9. Dr Robert Hodgson Present for all items
10. Ivan Koychev Present for all items
11. Dr Soo Fon Lim Present for all items
12. Dr Guy Makin Present for all items
13. Professor David Meads Present for all items
14. Giles Monnickendam Present for all items
15. Malcolm Oswald Present for all items
16. Dr Rebecca Payne Present for all items
17. Professor Chris Parker Items 5.1.3 to 5.2.2
18. Carole Pitkeathley Present for all items
19. Baljit Singh Present for all items
20. Professor John Watkins Present for all items
21. Dr Ed Wilson Present for all items

NICE staff present

Jasdeep Hayre, Associate Director Present for all items

Ross Dent, Associate Director Items 5 to 5.2.2

Gavin Kenny, role Present for all items

Louise Jafferally, role Items 5 to 5.2.2

Caron Jones, Heath Technology Assessment Adviser Items 1 to 4.2.2

Amy Crossley, Heath Technology Assessment Analyst Items 1 to 4.2.2

Maroulla Whiteley, Business Analyst, RIA Present for all items

Emilene Coventry, Senior Medical Editor Present for all items

Gemma Smith, Coordinator, COT Present for all items

Iain Cannell, Administrator, TA Present for all items

External review group representatives present

Brian O'Toole, Peninsula Technology Assessment Group Items 1 to 4.1.3

G.J. Melendez-Torres, Peninsula Technology Assessment Group Items 1 to 4.1.3

## Minutes

### Introduction to the meeting

* 1. The chair Dr Megan John welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted committee member apologies.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee noted that the minutes of the meeting held on Thursday 14 October would be confirmed at the next meeting scheduled for Wednesday 15 December.

### Appraisal of Fremanezumab for preventing migraine [ID3952]

* 1. Part 1 – Open session
		1. The chair welcomed the external review group representatives, and company representatives from Teva UK.
		2. The chair asked all committee members, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Professor David Meads declared financial interests as the University of Leeds has received funding from Janssen for research in an un-related area.
* It was agreed that his declaration would not prevent Professor Meads from participating in this section of the meeting.
* Committee member Dr Ed Wilson declared financial interests as Allergan, Janssen and Novartis are or have been clients of the company he works for in the last three years, but they have not worked on this appraisal.
* It was agreed that his declaration would not prevent Dr Wilson from participating in this section of the meeting.
* Committee Member Professor Rachel Elliott declared financial interests as she has received a fee from Janssen for a discussion on an unrelated topic [depression].
* It was agreed that her declaration would not prevent Professor Elliott from participating in this section of the meeting.
	+ 1. The Chair led a discussion of the consultation comments presented to the committee.
	1. Part 2 – Closed session [company representatives and external review group representatives were asked to leave the meeting]
		1. The committee then agreed on the content of the Appraisal Consultation Document [ACD] or the Final Appraisal Determination [FAD]. The committee decision was reached by consensus..
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD] of Final Appraisal Determination [FAD] in line with their decisions.
* further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/ta631>

### Appraisal of upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs [ID2690]

* 1. Part 2 – Closed session
		1. The chair welcomed committee members and NICE Staff to the meeting.
		2. The chair Dr Megan John asked all committee members, and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Professor David Meads declared financial interest as the University of Leeds has received funding from Abbvie, Janssen, Celgene and Sanofi for research in an un-related area.
* It was agreed that his declaration would not prevent Professor Meads from participating in this section of the meeting.
* Committee member Dr Ed Wilson declared financial interests as Amgen, Celgene, Janssen-Cilag, MSD, Novartis, Pfizer and Sanofi are or have been clients of the company he works for in the last 3 years, but they have not worked on this appraisal.
* It was agreed that his declaration would not prevent Dr Wilson from participating in this section of the meeting.
	+ 1. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Jasdeep Hayre.
	1. Part 2b – Closed session
		1. The committee then agreed on the content of the Appraisal Consultation Document [ACD]. or the Final Appraisal Determination [FAD]. The committee decision was reached through a vote by members..
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD] or Final Appraisal determination [FAD] in line with their decisions.
* further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10666> .

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Wednesday 15 December 2021 and will start promptly at 09.30.